We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Bridgebio Pharma Inc
12 own
16 watching
Current Price
$27.08
$-0.19
(-0.7%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
2,613.49M
52-Week High
36.36000
52-Week Low
6.64000
Average Volume
2.84M
Dividend Yield
--
P/E Ratio
--
Market Capitalization2,613.49M52-Week High36.3600052-Week Low6.64000Average Volume2.84MDividend Yield--P/E Ratio--What does the Bridgebio Pharma Inc do?
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing BBP-418, a substrate supplementation therapy for the treatment of limb-girdle muscular dystrophy type 2i. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Read More
How much money does Bridgebio Pharma Inc make?
News & Events about Bridgebio Pharma Inc.
TipRanks Financial Blog
3 months ago
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO Research Report) and Arcell... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO Research Report) and Arcellx...
Stock Options Channel
3 months ago
Investors eyeing a purchase of BridgeBio Pharma Inc (BBIO) shares, but cautious about paying the going market price of 15.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at ...
PR Newswire
5 months ago
Thinking about buying stock in Western Alliance Bancorp, Genprex, Windtree Therapeutics, BridgeBio Pharma, or PacWest Bancorp? Thinking about buying stock in Western Alliance Bancorp, Genprex, Windtree Therapeutics, BridgeBio Pharma, or PacWest Bancorp? PR Newswire NEW YORK, April 19, 2023 NEW...
Globe Newswire
5 months ago
PALO ALTO, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 7, 2023, the compensation committee of BridgeBios board of ...
Globe Newswire
6 months ago
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an oral presentation ...
Frequently Asked Questions
Frequently Asked Questions
What is Bridgebio Pharma Inc share price today?
Can Indians buy Bridgebio Pharma Inc shares?
How can I buy Bridgebio Pharma Inc shares from India?
Can Fractional shares of Bridgebio Pharma Inc be purchased?
What are the documents required to start investing in Bridgebio Pharma Inc stocks?
What is today’s traded volume of Bridgebio Pharma Inc?
What is today’s market capitalisation of Bridgebio Pharma Inc?
What is the 52-Week High and Low Range of Bridgebio Pharma Inc?
What percentage is Bridgebio Pharma Inc down from its 52-Week High?
What percentage is Bridgebio Pharma Inc up from its 52-Week Low?
Current Price
$27.08
$-0.19
(-0.7%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.